Company intelligence / Profile preview
MultiVir, Inc.
Houston, Texas, USAmultivir.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MultiVir has developed a pipeline of experimental tumor suppressor immune gene therapies and therapeutic vaccines. Its lead program—an oncolytic adenovirus-based gene therapy—has entered Phase I clinical trials for unspecified neoplasms. Other candidates include IL‑24 gene therapy for head and neck cancers and HSV Rb-p450 for colorectal cancer, both at earlier stages or pending trial initiation. No late-stage or commercialized products reported as of the latest available data.
- Therapeutic areas
- Oncology
- Modalities
- Gene therapy (including oncolytic viruses and immune gene therapies)Oncolytic adenoviruses, herpes simplex viruses (HSV), vaccinia virusesTherapeutic vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on MultiVir, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MultiVir, Inc..